Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric L Simpson

Showing results (181-190 of 315) with videos related to

Pageof 32
Sort By:
Journal of the American Academy of Dermatology|September 16, 2022
Itch-free state in patients with atopic dermatitis treated with ruxolitinib cream: A pooled analysis from two randomized phase 3 studiesAndrew Blauvelt, Jacek C Szepietowski, Kim Papp, et al.
The Journal of Dermatological Treatment|September 25, 2024
Disease burden and patient characteristics associated with systemic therapy utilization among adults with atopic dermatitis: data from CorEvitas Atopic Dermatitis RegistryJonathan I Silverberg, Linda Stein Gold, Seemal Desai, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 4, 2025
Dupilumab improves quality of life assessed by the Quality of Life in Hand Eczema QuestionnaireEric L Simpson, Marie-Louise A Schuttelaar, Sonja Molin, et al.
The Journal of Allergy and Clinical Immunology|October 6, 2014
Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis preventionEric L Simpson, Joanne R Chalmers, Jon M Hanifin, et al.
Advances in Therapy|January 21, 2026
Dupilumab Treatment Up to 5 Years Shows No Clinically Meaningful Changes in Laboratory Parameters in Adults with Moderate-to-Severe Atopic DermatitisEric L Simpson, Robert Bissonnette, Mette Deleuran, et al.
The Journal of Dermatological Treatment|December 22, 2022
Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trialsThomas Bieber, Norito Katoh, Eric L Simpson, et al.
Eclinicalmedicine|July 3, 2023
Efficacy and safety of topically applied therapeutic ammonia oxidising bacteria in adults with mild-to-moderate atopic dermatitis and moderate-to-severe pruritus: a randomised, double-blind, placebo-controlled, dose-ranging, phase 2b trialJonathan I Silverberg, Peter A Lio, Eric L Simpson, et al.
The British Journal of Dermatology|August 7, 2023
The Harmonising Outcome Measures for Eczema (HOME) implementation roadmapYael A Leshem, Eric L Simpson, Christian Apfelbacher, et al.
Acta Dermato-Venereologica|October 7, 2021
Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic DermatitisJonathan I Silverberg, Eric L Simpson, Mark Boguniewicz, et al.
American Journal of Clinical Dermatology|December 13, 2022
Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE TrialSonja Ständer, Shawn G Kwatra, Jonathan I Silverberg, et al.
Pageof 32

Showing results (181-190 of 315) with videos related to

Sort By:
Pageof 32
Journal of the American Academy of Dermatology|September 16, 2022
Itch-free state in patients with atopic dermatitis treated with ruxolitinib cream: A pooled analysis from two randomized phase 3 studiesAndrew Blauvelt, Jacek C Szepietowski, Kim Papp, et al.
The Journal of Dermatological Treatment|September 25, 2024
Disease burden and patient characteristics associated with systemic therapy utilization among adults with atopic dermatitis: data from CorEvitas Atopic Dermatitis RegistryJonathan I Silverberg, Linda Stein Gold, Seemal Desai, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 4, 2025
Dupilumab improves quality of life assessed by the Quality of Life in Hand Eczema QuestionnaireEric L Simpson, Marie-Louise A Schuttelaar, Sonja Molin, et al.
The Journal of Allergy and Clinical Immunology|October 6, 2014
Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis preventionEric L Simpson, Joanne R Chalmers, Jon M Hanifin, et al.
Advances in Therapy|January 21, 2026
Dupilumab Treatment Up to 5 Years Shows No Clinically Meaningful Changes in Laboratory Parameters in Adults with Moderate-to-Severe Atopic DermatitisEric L Simpson, Robert Bissonnette, Mette Deleuran, et al.
The Journal of Dermatological Treatment|December 22, 2022
Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trialsThomas Bieber, Norito Katoh, Eric L Simpson, et al.
Eclinicalmedicine|July 3, 2023
Efficacy and safety of topically applied therapeutic ammonia oxidising bacteria in adults with mild-to-moderate atopic dermatitis and moderate-to-severe pruritus: a randomised, double-blind, placebo-controlled, dose-ranging, phase 2b trialJonathan I Silverberg, Peter A Lio, Eric L Simpson, et al.
The British Journal of Dermatology|August 7, 2023
The Harmonising Outcome Measures for Eczema (HOME) implementation roadmapYael A Leshem, Eric L Simpson, Christian Apfelbacher, et al.
Acta Dermato-Venereologica|October 7, 2021
Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic DermatitisJonathan I Silverberg, Eric L Simpson, Mark Boguniewicz, et al.
American Journal of Clinical Dermatology|December 13, 2022
Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE TrialSonja Ständer, Shawn G Kwatra, Jonathan I Silverberg, et al.
Pageof 32